Assessing Novel RIPK2-MKK7 Interaction Inhibitors in Prostate Cancer Cell Lines
ISEF · 2025 Cellular and Molecular Biology Fourth Award
Overview
Metastatic prostate cancer (mPC) stands second in cancer-related mortality among men. As current treatment options are largely palliative, there is a dire need for novel therapeutic targets in mPC. Prior research has identified receptor-interacting protein kinase 2 (RIPK2) as a promising drug target in mPC, acting through a non-canonical RIPK2/MKK7/c-Myc signaling pathway. Selectively targeting the protein-protein interaction between RIPK2 and MKK7 has strong potential to inhibit RIPK2-driven PC metastasis while minimizing side effects, as this approach spares disrupting the canonical RIPK2 signaling pathway, crucial for immune response and wound healing. In this study, nine candidate small-molecule RIPK2-MKK7 inhibitors were tested in two prostate cancer cell lines: PC3 and 22Rv1. Western blotting was used to assess their effects on reducing phosphorylated c-Myc (S62) levels, a key oncoprotein and readout for RIPK2/MKK7/c-Myc pathway activity. Among the nine proprietary candidates (A-I), inhibitor H decreased p-c-Myc-S62 levels in both cell lines: 24% in PC3 cells (P=0.043) and 39% in 22Rv1 cells (P=0.042). Similarly, inhibitor F decreased p-c-Myc-S62 expression by 31% in PC3 cells (P=0.002). To determine whether the top inhibitors (F and H) reduce RIPK2-MKK7 interactions, a Duolink® proximity ligation assay was conducted, which allowed for the fluorescent detection of RIPK2-MKK7 interactions in situ. Inhibitors F and H significantly decreased RIPK2-MKK7 interactions: H resulted in a 46% reduction in PC3 and 38% in 22Rv1 while F resulted in a 38% reduction in both cell lines. This study represents an important first-step in the investigation of a protein-protein interaction as a novel target in mPC.
Awards (1)
- Fourth Award of $600 $600
Competition history
- ISEF 2025
Resources
Related projects
ISEF · 2022
Development of Novel, Selective, Orally Available Small Molecule CDK9 Inhibitors for Prostate Cancer Therapy - Mechanistic Studies
AJAS · 2026
Targeting RAGE: A Novel Therapeutic Strategy Against AGE-Mediated PCa Progression
JSHS · 2025
Targeting RAGE: A Novel Therapeutic Strategy Against AGE-Mediated Prostate Cancer Progression
CSEF · 2018
Analyzing the Effects of Interferon Signaling as a Novel Approach to Neuroendocrine Prostate Cancer Therapy
ISEF · 2016
An Analysis of Ectopic Expression of MicroRNAs Targeting the Androgen Receptor on the Viability of Prostate Cancer Cells
ISEF · 2023
Development of Selective MIZ-1 BTB Domain Inhibitors Targeting HUWE1 E3 Ligase in MYC-Driven Cancers
CSEF · 2015
Identification of NUSAP1 as a Novel Therapeutic Target for Aggressive Prostate Cancer
CSEF · 2008
The Inhibitory Effect of HKa on Prostate Cancer Line DU145 Is Mediated by Blocking Metastasis
Closest projects by meaning, across every fair and year in the corpus.
Browse more like this
Source: Regeneron International Science and Engineering Fair